Literature DB >> 8091843

Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines.

M Sugimoto1, K Yamanouchi.   

Abstract

This article reviews studies concerning the characteristics of a vaccinia virus strain, LC16m0, and its recombinant virus vaccines. The LC16m0 strain is one of several temperature-sensitive and further attenuated variants derived from the Lister (Elstree) strain of vaccinia virus, which has a proven safety record in human populations. Several types of recombinant vaccinia viruses expressing a foreign antigen gene from a pathogenic virus have been constructed using the LC16m0 strain as a vector, and their immunological and virological characteristics have been investigated extensively. These studies indicate that the LC16m0 strain has potential as a vector in a live recombinant vaccine. The advantages, disadvantages and future prospects of vector are discussed.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8091843     DOI： 10.1016/0264-410x(94)90215-1

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  10 in total

1.  Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain.

Authors:  F Scheiflinger; F G Falkner; F Dorner
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

Review 3.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

4.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

5.  Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.

Authors:  Hiroyuki Yokote; Yasuhiko Shinmura; Tomomi Kanehara; Shinichi Maruno; Masahiko Kuranaga; Hajime Matsui; So Hashizume
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

6.  Specific temperature-induced perturbations of secondary mRNA structures are associated with the cold-adapted temperature-sensitive phenotype of influenza A virus.

Authors:  Andrey Chursov; Sebastian J Kopetzky; Ignaty Leshchiner; Ivan Kondofersky; Fabian J Theis; Dmitrij Frishman; Alexander Shneider
Journal:  RNA Biol       Date:  2012-09-20       Impact factor: 4.652

7.  Developing new smallpox vaccines.

Authors:  S R Rosenthal; M Merchlinsky; C Kleppinger; K L Goldenthal
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

8.  Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function.

Authors:  Motomu Nakatake; Hajime Kurosaki; Nozomi Kuwano; Kosuke Horita; Mai Ito; Hiromichi Kono; Tomotaka Okamura; Kosei Hasegawa; Yasuhiro Yasutomi; Takafumi Nakamura
Journal:  Mol Ther Oncolytics       Date:  2019-05-21       Impact factor: 7.200

Review 9.  LC16m8: an attenuated smallpox vaccine.

Authors:  Julie Kenner; Fiona Cameron; Cyril Empig; David V Jobes; Marc Gurwith
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

10.  Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver.

Authors:  Satoshi Sekiguchi; Kiminori Kimura; Tomoko Chiyo; Takahiro Ohtsuki; Yoshimi Tobita; Yuko Tokunaga; Fumihiko Yasui; Kyoko Tsukiyama-Kohara; Takaji Wakita; Toshiyuki Tanaka; Masayuki Miyasaka; Kyosuke Mizuno; Yukiko Hayashi; Tsunekazu Hishima; Kouji Matsushima; Michinori Kohara
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.